Abstract 4842
Background
The incidence of pancreatic cancer (PAC) has continued to rise in recent years. PAC can be divided into head of PAC (HPAC) and body/tail of PAC (BTPAC) by the anatomical location. The patients (pts) with BTPAC are usually diagnosed at relatively advanced stage and had worse survival than those with HPAC. The comparative molecular signatures between different locations in Chinese PAC pts remain unclear.
Methods
154 tumor specimens (HPAC, N = 85; BTPAC, N = 69) and matched normal blood samples of Chinese PAC pts were detected and analyzed in a CAP&CLIA certified laboratory (OrigiMed company) with Yuansu panel including 450 genes. Total 100 males (65%) and 54 females (35%) with a mean age of 61 years old (yrs) were enrolled. We measured the somatic variations and calculated tumor mutational burden (TMB) after filtering known driver mutations (muts). Meanwhile, germline muts were analyzed among the tumor susceptibility genes. Fisher tests were used for comparative analyses.
Results
The median age in HPAC and BTPAC was 60 yrs and 62 yrs. Pts with stage 3&4 accounted for 40% and 60% in HPAC and BTPAC (P<0.05). Genomic alterations of KRAS and SMAD4 were significantly more prevalent in BTPAC (KRAS in BTPAC vs. HPAC= 97% vs. 82%, P=0.004; SMAD4 in BTPAC vs. HPAC= 42% vs. 21%, P=0.008). 2 NTRK3 fusions (3%) were found in BTPAC but 0 in HPAC. Additionally, muts frequency in Wnt pathway was 57% in BTPAC, whereas 37% in HPAC (P=0.02). No significant difference was found in TP53 (83% vs. 81%), CDKN2A (32% vs. 27%) and germline muts frequency (12% vs. 14%) between BTPAC and HPAC, nor in the mean TMB value (3.22 muts/Mb vs. 3.59 muts/Mb). For HPAC, there were more muts in HR pathway genes (24% vs. 19%), although the difference was not statistical significance. 2 BRCA2 germline muts were found in HPAC but neither BRCA1 nor BRCA2 was found in BTPAC.
Conclusions
Genomic pattern did not show apparent difference between the anatomic locations of PAC. However, we found more driver muts in KRAS and SMAD4 and more Wnt pathway muts related to proliferation and metastasis in BTPAC. Further research should be done to better understand the cancer biology among the locations and identify more therapy targets for precision medicine.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
733 - Clinical experience: ramucirumab with FOLFIRI/XELIRI as a second line for patients with metastatic gastric cancer
Presenter: Tatiana Titova
Session: Poster Display session 2
Resources:
Abstract
2186 - Efficacy and safety of apatinib for the treatment of AFP-producing gastric cancer
Presenter: Ningning Li
Session: Poster Display session 2
Resources:
Abstract
3172 - Apatinib in combination with docetaxol and S1 chemotherapy in the first line treatment of metastatic gastric cancer
Presenter: Ling Xia
Session: Poster Display session 2
Resources:
Abstract
3982 - Parameters of local cellular immunity in metastatic gastric cancer
Presenter: Aleksandr Sagakyants
Session: Poster Display session 2
Resources:
Abstract
5102 - Germline pathogenic mutations in Chinese patients with gastric cancer identified by next-generation sequencing (NGS)
Presenter: Xiaotian Zhang
Session: Poster Display session 2
Resources:
Abstract
5012 - Inhibition of the PI3K pathway in HER2-positive gastric cancer
Presenter: Sinead Toomey
Session: Poster Display session 2
Resources:
Abstract
4803 - Investigation on gastric cancer susceptibility genes in Chinese early-onset diffuse gastric cancer
Presenter: Yi Feng
Session: Poster Display session 2
Resources:
Abstract
4778 - A correlation analysis between survival rate and the characteristic gene of gastric cancer based on bioinformatics analysis
Presenter: Yi-wen Zhang
Session: Poster Display session 2
Resources:
Abstract
4805 - Phase I study of apatinib combined with POF (paclitaxel plus FOLFOX) in patients (pts) with treatment-naïve advanced gastric cancer (TNAGC)
Presenter: Rongbo LIN
Session: Poster Display session 2
Resources:
Abstract
3248 - Second-line palliative systemic treatment for synchronous metastatic esophagogastric cancer: a population-based study
Presenter: Willemieke Dijksterhuis
Session: Poster Display session 2
Resources:
Abstract